跳至主要内容
临床试验/CTRI/2025/01/079365
CTRI/2025/01/079365招募中Unknown

A PMCF study to evaluate the safety and efficacy of the Bovine Pericardial Tissue Patch in Vascular Surgeries

Tisgenx, Inc.1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2025年2月3日最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
15
试验地点
1
主要终点
1.Safety: Incidence of adverse events related to the use of bovine pericardial patch, including

研究概览

简要总结

A PMCF study to evaluate the safety and efficacy of the Bovine Pericardial Tissue Patch in Vascular Surgeries.

Study Design-The study will be single centric, prospective, interventional clinical study.

Primary Objectives:

• Safety: Incidence of adverse events related to the use of bovine pericardial patch, including

infections, thrombosis, and allergic reactions.

• Efficacy: Patency rates of vascular grafts assessed through imaging studies - Doppler ultrasound

at specified follow-up intervals.

• Patch handling and characteristics

Secondary Objectives:

• Patients will be examined post-surgery by evaluating the occurrence of wound infection,

hematoma, partial thrombosis, thrombotic occlusion, pseudoaneurysm, stroke, myocardial

infarction, carotid artery thrombosis, paralysis, restenosis

• Mortality rate.

Subject Types

The study population will consist of subjects in the following group: -

Patients scheduled for vascular surgery requiring a patch graft.

Population and Enrolment

A total of 15 subjects will be recruited for the study of the product Bovine Pericardial Tissue Patch for

vascular surgery.

Inclusion and Exclusion criteria

Inclusion Criteria

• Adults aged 18 years and older undergoing vascular surgery requiring a patch graft.

Exclusion Criteria

• Patients with known allergies to bovine products or pre-existing conditions contraindicating the

use of bovine pericardial patches

• Patients with uncontrolled infections

• Pregnant patients.

Duration of Data collection

The duration of data collection will be 1 year

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 75.00 Year(s)(—)
性别
All

入选标准

  • Adults aged 18 years and older undergoing vascular surgery requiring a patch graft.

排除标准

  • 1.Patients with known allergies to bovine products or pre-existing conditions contraindicating the use of bovine pericardial patches.
  • 2.Patients with uncontrolled infections 3.Pregnant patients.

结局指标

主要结局

1.Safety: Incidence of adverse events related to the use of bovine pericardial patch, including

时间窗: The study will follow up with patients for a minimum of 1 month postoperatively to evaluate short-term | outcomes. Long-term outcomes will also be assessed during subsequent follow-up periods, 3 months,6 months and 1 year.

infections, thrombosis, and allergic reactions.

时间窗: The study will follow up with patients for a minimum of 1 month postoperatively to evaluate short-term | outcomes. Long-term outcomes will also be assessed during subsequent follow-up periods, 3 months,6 months and 1 year.

2.Efficacy: Patency rates of vascular grafts assessed through imaging studies - Doppler ultrasound

时间窗: The study will follow up with patients for a minimum of 1 month postoperatively to evaluate short-term | outcomes. Long-term outcomes will also be assessed during subsequent follow-up periods, 3 months,6 months and 1 year.

at specified follow-up intervals.

时间窗: The study will follow up with patients for a minimum of 1 month postoperatively to evaluate short-term | outcomes. Long-term outcomes will also be assessed during subsequent follow-up periods, 3 months,6 months and 1 year.

3.Patch handling and characteristics

时间窗: The study will follow up with patients for a minimum of 1 month postoperatively to evaluate short-term | outcomes. Long-term outcomes will also be assessed during subsequent follow-up periods, 3 months,6 months and 1 year.

次要结局

  • 1.Patients will be examined post-surgery by evaluating the occurrence of wound infection,(hematoma, partial thrombosis, thrombotic occlusion, pseudoaneurysm, stroke, myocardial)

研究者

发起方
Tisgenx, Inc.
申办方类型
Other [Medical Equipment Manufacturing]
责任方
Principal Investigator
主要研究者

Dr Robbie K George

Mazumdar Shaw Medical Center- a unit of Narayana Health

研究点 (1)

Loading locations...

相似试验